Lumos Pharma Inc logo

LUMO

Lumos Pharma Inc

$8.64

Earnings Summary

Revenue
$0.11Mn
Net Profits
$-7.72Mn
Net Profit Margins
-6954.95%

Highlights

Revenue:

Lumos Pharma Inc’s revenue jumped 177.5% since last year same period to $0.11Mn in the Q1 2022. On a quarterly growth basis, Lumos Pharma Inc has generated 1236.13% jump in its revenue since last 3-months.

Net Profits:

Lumos Pharma Inc’s net profit jumped 10.55% since last year same period to $-7.72Mn in the Q1 2022. On a quarterly growth basis, Lumos Pharma Inc has generated -131.18% fall in its net profits since last 3-months.

Net Profit Margins:

Lumos Pharma Inc’s net profit margin jumped 67.77% since last year same period to -6954.95% in the Q1 2022. On a quarterly growth basis, Lumos Pharma Inc has generated 97.26% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Lumos Pharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.99
EPS Estimate Current Year
-0.99

Highlights

EPS Estimate Current Quarter:

Lumos Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.99 - a -11.24% fall from last quarter’s estimates.

EPS Estimate Current Year:

Lumos Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.99.

Key Ratios

Key ratios of the Lumos Pharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.92
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.33
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Lumos Pharma Inc’s earning per share (EPS) jumped 11.54% since last year same period to -0.92 in the Q1 2022. This indicates that the Lumos Pharma Inc has generated 11.54% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Lumos Pharma Inc’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lumos Pharma Inc’s return on equity (ROE) stands at -0.33.

Dividend Per Share (DPS):

Lumos Pharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.89
-0.92
-3.37%

Company Information

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU.

Organisation
Lumos Pharma Inc
Employees
29
Industry
Health Technology